AngioDynamics (ANGO) is scheduled to report earnings for the quarter ending August 31, 2025, on October 2, with analysts forecasting a loss of $-0.14 per share, a 27.27% decrease year-over-year. Despite this negative consensus and a 2026 P/E ratio of -37.23 against an industry average of 7.60, the medical instruments company has consistently beaten earnings expectations in the past year, suggesting potential for an upside surprise.
AngioDynamics, Inc. (ANGO) is approaching its earnings announcement for the quarter ending August 31, 2025, with a consensus earnings per share (EPS) forecast of $-0.14. This projection represents a significant 27.27% deterioration compared to the same quarter last year, signaling underlying weakness in profitability. Compounding this negative outlook, the company's projected 2026 Price to Earnings ratio stands at a deeply negative -37.23, which contrasts sharply with the positive industry average of 7.60, indicating that analysts expect losses to continue. However, these bearish metrics are challenged by the company's recent performance history. Over the past year, ANGO has successfully beaten analyst expectations in every single quarter. Notably, one of these beats was a substantial 76.92%, suggesting a recurring pattern where consensus forecasts may be overly conservative, creating a potential for a positive surprise despite the negative guidance.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
moderately negative
Sentiment Score
-0.45
Ticker Sentiment
